• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Novel Coronavirus (NCoV) - Multistate - Severe respiratory syndrome (ECDC/CDTR, May 7 2013)

Giuseppe

Emeritus
[Source: European Centre for Disease Prevention and Control (ECDC), full PDF document: (LINK). Extract.]


COMMUNICABLE DISEASE THREATS REPORT

Week 18, 28 April-4 May 2013

(?)


Novel Coronavirus - Multistate - Severe respiratory syndrome

Opening date: 24 September 2012 Latest update: 2 May 2013


Epidemiological summary

The first described case of novel coronavirus infection was a 60-year-old male resident of Saudi Arabia who died from severe pneumonia complicated by renal failure in June 2012. A previously unknown coronavirus isolated from this patient was identified and named Human Coronavirus-Erasmus Medical Centre (HCoV-EMC/2012). In September 2012, a second case was reported, a Qatari man, who was transferred for care to Europe. In November 2012, additional cases with similar symptomatology were diagnosed in Qatar and Saudi Arabia. These included a family cluster of three confirmed and one probable case.

Subsequently, two fatal cases were confirmed retrospectively by testing stored samples from a cluster of 11 cases of lower respiratory infection linked to a hospital in Jordan in April 2012.

In February 2013, a cluster of novel coronavirus cases was reported from the United Kingdom where the index case had travelled to Pakistan and Saudi Arabia ten days before symptom onset and where contact tracing identified two secondary cases among family members without recent travel. One person died and the other had a self-limiting influenza-like illness which did not require hospitalisation. Three additional sporadic cases have been reported since February, all from Saudi Arabia and fatal.

On 25 March Robert Koch Institute (RKI), Germany, reported the second imported case from the country. The patient, a 73 year old male with underlying clinical conditions, had been hospitalised in the United Arab Emirates and transferred to a hospital in Germany (Munich) for specific clinical care where subsequent diagnosis of nCoV infection was confirmed.

The patient died on 26 March.

On 1 May, the Ministry of Health in Saudi Arabia reported seven recent cases, five of whom fatal. All fatal cases were from the eastern Al Ahsa governorate.

This brings the number of cases to 24 globally, including 16 deaths.

(?)


ECDC assessment

Research on the complete genome sequence of the novel coronavirus has characterised the virus as a new genotype that is closely related to bat coronaviruses. It is genetically distinct from SARS-CoV. The routes of transmission to humans and the virus reservoir have not been determined.

This is a common problem with emerging zoonoses where there is often simultaneous possibilities including environmental, animal and human exposures.

The cluster of three cases in the UK is evidence of limited human-to-human transmission. However, several hundred contacts of the UK cluster and the case treated in Germany have now been actively followed up without evidence of novel coronavirus infection indicating that the risk of transmission remains low.

These new cases reported on 1 May do not change ECDC risk assessment.


Actions

ECDC updated its rapid risk assessment, and published an epi-update on 27 March (Epidemiological update ECDC). The results of an ECDC coordinated survey on laboratory capacity for testing for the novel coronavirus in Europe were published in EuroSurveillance. On 18 March, WHO posted interim surveillance recommendations for human infection with novel coronavirus on their website.

ECDC is closely monitoring the situation in collaboration with WHO and the European Union Member States.

(?)


-
------
 
Back
Top Bottom